Daniela Krummenacher

Roche (Switzerland) — Switzerland

Computer Science · Physical Sciences

3h-index168citations17works0.02yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Computational Drug Discovery Methods(16), Melanoma and MAPK Pathways(15), Protein Kinase Regulation and GTPase Signaling(10), Cancer Mechanisms and Therapy(3), Alzheimer's disease research and treatments(2)

Publications17 total

Discovery of Orally Available and Brain Penetrant AEP Inhibitors
Journal of Medicinal Chemistry·2023· 14 citedOpen Access
Supplementary Data from Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor
2023Open Access
Supplementary Data from Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor
2023Open Access
Supplementary Data from Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor
2023Open Access
Supplementary Data from Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor
2023Open Access
Supplementary Data from Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor
2023Open Access
Data from Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor
2023Open Access
Supplementary Table from Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor
2023Open Access
Data from Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor
2023Open Access
Supplementary Data from Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor
2023Open Access
Supplementary Data from Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor
2023Open Access
Supplementary Table from Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor
2023Open Access
Supplementary Data from Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor
2023Open Access
Supplementary Data from Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor
2023Open Access
Supplementary Data from Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor
2023Open Access
Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor
Clinical Cancer Research·2021· 18 citedOpen Access
β-Secretase (BACE1) Inhibitors with High in Vivo Efficacy Suitable for Clinical Evaluation in Alzheimer’s Disease
Journal of Medicinal Chemistry·2013· 136 citedOpen Access

Frequent Co-authors

David S. Hewings(16), Jürgen Wichmann(15), Caroline Rynn(15), Thomas Friess(15), Jeannine Petrig-Schaffland(15), Martin Kornacker(15), Jasmin Emmenegger(15), Jan Eckmann(15), Frank Herting(15), Nicolas Frances(15), Daniel Hunziker(15), Dominik Rüttinger(15), Alison Ribeiro(15), Marina Bacac(15), Alessandro Brigo(15), Reinhard Dummer(15), Gabriel Schnetzler(15), Bruno Martoglio(15), James R. Bischoff(15), Piergiorgio Pettazzoni(15)